Chromosomal Instability in Genome Evolution: From Cancer to Macroevolution

Biology (Basel). 2023 Apr 28;12(5):671. doi: 10.3390/biology12050671.

Abstract

The integrity of the genome is crucial for the survival of all living organisms. However, genomes need to adapt to survive certain pressures, and for this purpose use several mechanisms to diversify. Chromosomal instability (CIN) is one of the main mechanisms leading to the creation of genomic heterogeneity by altering the number of chromosomes and changing their structures. In this review, we will discuss the different chromosomal patterns and changes observed in speciation, in evolutional biology as well as during tumor progression. By nature, the human genome shows an induction of diversity during gametogenesis but as well during tumorigenesis that can conclude in drastic changes such as the whole genome doubling to more discrete changes as the complex chromosomal rearrangement chromothripsis. More importantly, changes observed during speciation are strikingly similar to the genomic evolution observed during tumor progression and resistance to therapy. The different origins of CIN will be treated as the importance of double-strand breaks (DSBs) or the consequences of micronuclei. We will also explain the mechanisms behind the controlled DSBs, and recombination of homologous chromosomes observed during meiosis, to explain how errors lead to similar patterns observed during tumorigenesis. Then, we will also list several diseases associated with CIN, resulting in fertility issues, miscarriage, rare genetic diseases, and cancer. Understanding better chromosomal instability as a whole is primordial for the understanding of mechanisms leading to tumor progression.

Keywords: cancer; chromosomal instability; genome evolution; meiosis; micronuclei; speciation; structural variant.

Publication types

  • Review

Grants and funding

V.C. is funded by the Spanish association against the Cancer AECC investigator grant (INVES20033COMA) and from the Fundación Vencer el Cancer. M.C.-P. and V.C. are funded by the MSCA IF grant coDNAres 101023902 (M.C.-P.) and Onco-inflammation 101026137 (V.C.).